-
-
Call more information
660-596-2224 -
The US Food and Drug Administration (FDA) has approved an abuse-deterrent extended-release formulation of oxycodone (Targiniq ER, Purdue Pharma LP), a combination of oxycodone hydrochloride and naloxone hydrochloride, the agency announced today. The new formulation is approved to treat pain severe enough to require daily, around-the-clock, long-term opioid treatment, for which alternative treatment options are […]
Read MoreStan Xuhui Li, MD, of Hamilton, New Jersey, was a full-time anesthesiologist at a local hospital who had a sideline. On weekends, the 60-year-old Dr. Li saw patients in a pain-management clinic 80 miles away in the Queens borough of New York City. A jury in a New York state court concluded on July 18 […]
Read MoreEvery leader is a coach to those who look to them for guidance. Your job as a leader is to be there when one of your employees are in a rut, but if you consistently offer them a gift-wrapped solution, those employees will forfeit their problem-solving skills in the process. Eventually, a new problem manifests […]
Read MoreOctober 1st, 2015, is the deadline for healthcare providers to implement the twice-delayed ICD-10 code set, federal officials confirm. HHS will release the final rule, Administrative Simplification: Change to the Compliance Date for the International Classification of Diseases, 10th Revision (ICD–10–CM and ICD-10-PCS) Medical Data Code Sets, in the Federal Register August 4. The one-year […]
Read MorePublished in Oral Oncol. 2014 Jul 4. pii: S1368-8375(14)00172-9 Authors: Bossi P et al BACKGROUND: Painful mucositis is one of the most distressing toxicities of chemoradiotherapy (CRT) for head and neck cancer (HNC), with the characteristics of incidental predictable breakthrough pain (BTP) during swallowing. Fentanyl pectin nasal spray (FPNS) could be a good therapeutic option. […]
Read More